Haemonetics (NYSE:HAE) announced that it acquired next-generation whole blood coagulation testing system developer Enicor GmbH for an undisclosed amount.
Munich, Germany-based Enicor develops the ClotPro system designed for viscoelastic diagnostics touted to offer more assays than any other hemostasis analyzer on the market. Haemonetics said in a news release that ClotPro is set to be coupled with its TEG 5000 hemostasis analyzer and TEG 6s hemostasis analyzer with site-of-care technology.
ClotPro is designed with active tip technology to reduce the need for manual pipetting and mitigate the potential for error while eliminating reagent handling. It received CE Mark approval in 2019 and is currently available in select European and Asian markets, although it is not available in the U.S.
Under the terms of the acquisition, Boston-based Haemonetics has acquired all of the outstanding share capital belonging to Enicor. Enicor CEO Dr. Andreas Calatzis is set to join Haemonetics as VP & GM of Enicor and work closely with the company’s R&D and clinical functions departments.
“The Enicor team and technology are a natural fit for Haemonetics’ hospital business,” Haemonetics global hospital president Stew Strong said in the news release. “The science behind the ClotPro analyzer and its related active tip technology will be assets as we drive our innovation agenda forward.
Calatzis added that Enicor’s vision has always been to extend the diagnostic options for clinics worldwide with respect to the management of blood coagulation disorders.
“With its leadership position in whole blood coagulation testing and its global reach, Haemonetics is the ideal company to accelerate clinical adoption and further develop our technology,” Calatzis said. “This will also provide our employees with an even greater opportunity to deliver innovation while advancing care for healthcare providers and ultimately patients.”
